..................genannt GILENYA von Novartis, im März 2011 in Europa zugelassen und wie genau es Herr Kappos, "Miterfinder" von GILENYA, Universität Basel, mit der Offenlegung seiner Interessenkonflikte nimmt - Kognitive Störungen Herr Doktor?? - brain fog???..................
+++++++++++++++++++++++++++++++++++++++++++++++++
Ein Blick in öffentlich zugängliche Publikationen genügt um Antworten zu finden!
Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer L, Sandbrink R, Kappos L, Uitdehaag BM. MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. BMC Neurol. 2009;9:19. http://www.biomedcentral.com/1471-2377/9/19
Competing interests:
"This study was sponsored by Bayer Schering Pharma AG, Berlin, Germany. Dr Nielsen has nothing to disclose. Dr Pohl has received personal compensation for activities with Schering AG as an employee. Consultancy for Schering, Aventis, UCB, Roche, Serono, Novartis. Dr Freedman has received personal compensation for activities with Bayer-Schering Pharmaceuticals, Merck-Serono, Pfizer Inc, Teva Neuroscience, Biogen Idec, Genentech, Inc. and BioMS as a consultant and advisory board member. Dr Edan has nothing to disclose. Prof Miller has received personal compensation for activities with Biogen Idec, GlaxoSmithKline, Inc., and Schering AG as a consultant. Prof Miller has received personal compensation in an editorial capacity for Journal of Neurology. Prof Miller has received research support from Biogen Idec., GlaxoSmithKline, Inc., and Schering AG. Dr Kappos has nothing to disclose. Dr Bauer has received personal compensation for activities with Schering AG as an employee. Dr Rupert Sandbrink received personal compensation from Schering AG as a salaried employee of this company. Prof Polman has received consulting fees from Biogen Idec, Schering AG, Teva, Serono, Novartis, GlaxoSmithKline, Novartis, and Teva. In the past year, dr. Uitdehaag has received compensation for consultancy from Novartis and Merck Serono. In the past year, dr. Uitdehaag received personal compensation from Ariez Medical Publishing for serving as a jounal editor. The institute for which dr Uitdehaag works received financieal support for research activities from Biogen Idec, Bayer Schering Pharma, GlaxoSmithKline, Novartis, Merck Serono and Teva."
“Competing interests: Dr Kappos has nothing to disclose.”
"Deutsch: Konkurrierende Interessen (=Interessenkonflikte): Dr. Kappos hat nichts offenzulegen."
Was verlangt die Anleitung für Autoren beim BMC Journal ("Instructions for BMC Neurology authors" on competing interests http://www.biomedcentral.com/bmcneurol/ifora/#interests)?
„Competing interests A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment were they to become public after the publication of the manuscript.
Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.”
Deutsch: „Ein konkurrierendes Interesse existiert, wenn die Interpretation von Daten oder die Präsentation von
Informationen durch persönliche oder finanzielle Verbindungen mit anderen Personen oder Organisationen beeinflusst sein könnte. Autoren sollten alle finanziellen konkurrierenden Interessen offenlegen, aber auch alle nicht-finanziellen konkurrierenden Interessen, welche zu Verlegenheit Anlass geben, wenn diese nach der Publikation öffentlich werden.
Die Autoren sind verpflichtet eine Deklaration von konkurrierenden Interessen auszufüllen. Alle konkurrierenden Interessen, welche deklariert wurden, werden am Ende des publizierten Artikels aufgelistet. Wenn ein Autor keine konkurrierenden Interessen angibt, wird der in etwa der folgende Text wiedergegeben "Der Autor deklariert, dass er keine konkurrierenden Interessen hat".
(Im übrigen verpflichten die Richtlinien der FMH von 2006 alle Schweizer Ärzte zur Offenlegung von Interessenbindungen bei der Publikation und der Präsentation von Forschungsresultaten, wie ich bereits angegeben habe.)
Wie wir bereits wissen hat jedoch Prof. Dr. med. Kappos Interessenkonflikte offenzulegen. Und zwar finanzielle Verbindungen mit 22 pharmazeutischen Unternehmen. Zur Repetition hier die Angaben vom New England Journal of Medicine von 2010 und 2006:
Kappos L et al. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. N Engl J Med 2010; 362:387-401 February 4, 2010 http://www.nejm.org/doi/full/10.1056/NEJMoa0909494
“Dr. Kappos, serving as a consultant or a member or chair of a steering committee, data and safety monitoring board, or advisory board in clinical trials sponsored by Accorda, Actelion, Allergan, Allozyne, Bayer Schering, Biogen Idec, Biogen-Dompé, Boehringer Ingelheim, Genmab, GlaxoSmithKline, MediciNova, Merck Serono, Novartis, Roche, Sanofi-Aventis, Santhera, Teva Pharmaceuticals, UCB Pharma, and Wyeth, receiving lecture fees from Biogen Idec, Helvea, GlaxoSmithKline, Mediservice and Merck Serono, and receiving grant support from Bayer Schering, Biogen Idec, CSL Behring, Genmab, Genzyme, GlaxoSmithKline, MediciNova, Merck Serono, Novartis, Novartis Foundation, Roche, Santhera, Sanofi-Aventis, and UCB Pharma.”
Kappos L, et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 14 Sep 2006;355(11):1124-1140. http://www.nejm.org/doi/full/10.1056/NEJMoa052643
“Dr. Kappos reports having participated as principal investigator, member, or chair of planning and steering committees or advisory boards in clinical trials of multiple sclerosis sponsored by Abbott, Bayer, Bayhill, Berlex, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Centocor, Eisai, Elan, Genzyme, GlaxoSmithKline, Immune Response, Neurocrine, Novartis, Sanofi-Aventis, Schering, Serono, Roche, Teva, UCB Pharma, and Wyeth and having received lecture fees from one or more of the above-listed companies.”
Aufgrund dieser Angaben hätte Prof. Dr. med. Kappos seine Interessenkonflikte im BMC Neurol. 2009 Artikel deklarieren und offenlegen müssen.!
Warum hat er es nicht gemacht?
- Missverständnis der Richtlinien?
- Vergesslichkeit?
- Unehrlichkeit?
Prof. Dr. med. Kappos beschäftigt sich mich komplizierten neuroimmunologischen Sachverhalten.*
Prof. Dr. med. Kappos ist einer der Hauptautoren einer Studie, die wahrscheinlich zur Zulassung der ersten MS-Pille (Fingolimod) führt.
Prof. Dr. med. Kappos ist im Vorstand der MS-Gesellschaft.
Prof. Dr. med. Kappos ist der Präsident des Wissenschaftlichen Beirates der MS-Gesellschaft.
Prof. Dr. med. Kappos ist im Ärztlichen Beirat der DMSG.
Prof. Dr. med. Kappos ist im Exekutiv-Komitee der grössten MS-Konferenz in Europa.
Prof. Dr. med. Kappos ist Professor der öffentlich finanzierten Universität Basel.
*) A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol. 2010 Mar 30;220(1-2):114-9.
Alles verantwortungsvolle Aufgaben, die ein hohes Maß an Sachverstand und Glaubwürdigkeit verlangen.
Einleitung zur Offenlegung von Interessenkonflikten von Ärzten (Prof. Kappos, Uni Basel) gravierende Lücken bei hohen Beträgen!
http://www.facebook.com/notes/venose-multiple-sklerose-cvi-svi-ccsvi/einleitung-zur-offenlegung-von-interessenkonflikten-von-arzten-prof-kappos-uni-b/424923086183
Quelle: http://csvi-ms.net/forum/viewtopic.php?f=2&t=671&p=9065#p9065
++++++++++++++++++++++++++++++++++++++++++++++++++++
ENGLISH:
The newest Novartis's MS-Poison called GILENYA, got EU approval in March 2011
…and how serious Mr. Kappos, "co-inventor" of GILENYA, University of Basel CH, is taking his obligation to declare all his conflict of interests (COI) – Cognitive issues doctor?? – to much brain fog???..................
Let’s have a look in publicly accessible publication that should be enough to get an answer. Here we go:
Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer L, Sandbrink R, Kappos L, Uitdehaag BM. MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. BMC Neurol. 2009;9:19. http://www.biomedcentral.com/1471-2377/9/19
Competing interests:
"This study was sponsored by Bayer Schering Pharma AG, Berlin, Germany. Dr Nielsen has nothing to disclose. Dr Pohl has received personal compensation for activities with Schering AG as an employee. Consultancy for Schering, Aventis, UCB, Roche, Serono, Novartis. Dr Freedman has received personal compensation for activities with Bayer-Schering Pharmaceuticals, Merck-Serono, Pfizer Inc, Teva Neuroscience, Biogen Idec, Genentech, Inc. and BioMS as a consultant and advisory board member. Dr Edan has nothing to disclose. Prof Miller has received personal compensation for activities with Biogen Idec, GlaxoSmithKline, Inc., and Schering AG as a consultant. Prof Miller has received personal compensation in an editorial capacity for Journal of Neurology. Prof Miller has received research support from Biogen Idec., GlaxoSmithKline, Inc., and Schering AG. Dr Kappos has nothing to disclose. Dr Bauer has received personal compensation for activities with Schering AG as an employee. Dr Rupert Sandbrink received personal compensation from Schering AG as a salaried employee of this company. Prof Polman has received consulting fees from Biogen Idec, Schering AG, Teva, Serono, Novartis, GlaxoSmithKline, Novartis, and Teva. In the past year, dr. Uitdehaag has received compensation for consultancy from Novartis and Merck Serono. In the past year, dr. Uitdehaag received personal compensation from Ariez Medical Publishing for serving as a jounal editor. The institute for which dr Uitdehaag works received financieal support for research activities from Biogen Idec, Bayer Schering Pharma, GlaxoSmithKline, Novartis, Merck Serono and Teva."
“Competing interests: Dr Kappos has NOTHING to disclose.”
What does the “Instructions for BMC Neurology authors" on competing interests require? http://www.biomedcentral.com/bmcneurol/ifora/#interests)?
„Competing interests A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment were they to become public after the publication of the manuscript.
Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.”
(BTW the Instructions of the FMH published in 2006, places all physicians from Switzerland under the obligation to declare their COIs in every publication and presentations of any scientific finding.)
How we already know does Prof. Dr. med. Kappos have to declare a lot of COIs. In fact he has financial connections to 22 pharmaceutical companies.
For repetition here the statements of the New England Journal of Medicine , 2010 & 2006:
Kappos L et al. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. N Engl J Med 2010; 362:387-401 February 4, 2010 http://www.nejm.org/doi/full/10.1056/NEJMoa0909494
“Dr. Kappos, serving as a consultant or a member or chair of a steering committee, data and safety monitoring board, or advisory board in clinical trials sponsored by Accorda, Actelion, Allergan, Allozyne, Bayer Schering, Biogen Idec, Biogen-Dompé, Boehringer Ingelheim, Genmab, GlaxoSmithKline, MediciNova, Merck Serono, Novartis, Roche, Sanofi-Aventis, Santhera, Teva Pharmaceuticals, UCB Pharma, and Wyeth, receiving lecture fees from Biogen Idec, Helvea, GlaxoSmithKline, Mediservice and Merck Serono, and receiving grant support from Bayer Schering, Biogen Idec, CSL Behring, Genmab, Genzyme, GlaxoSmithKline, MediciNova, Merck Serono, Novartis, Novartis Foundation, Roche, Santhera, Sanofi-Aventis, and UCB Pharma.”
Kappos L, et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 14 Sep 2006;355(11):1124-1140. http://www.nejm.org/doi/full/10.1056/NEJMoa052643
“Dr. Kappos reports having participated as principal investigator, member, or chair of planning and steering committees or advisory boards in clinical trials of multiple sclerosis sponsored by Abbott, Bayer, Bayhill, Berlex, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Centocor, Eisai, Elan, Genzyme, GlaxoSmithKline, Immune Response, Neurocrine, Novartis, Sanofi-Aventis, Schering, Serono, Roche, Teva, UCB Pharma, and Wyeth and having received lecture fees from one or more of the above-listed companies.”
Based on this information Prof. Dr. med. Kappos had to declare all his COIs in the BMC Neurol. 2009 article!
Where is his problem?
- Was it a misunderstanding of the rules?
- Did he just forget it [brain fog]?
- Dishonesty?
Prof. Dr. med. Kappos is engaged in doing very complicated med. neuroimmunological ascertainment.*
Prof. Dr. med. Kappos is one of the main authors of a study which most likely will lead to an approval of the first MS-Pill (GILENYA/Fingolimod).
Prof. Dr. med. Kappos is leading member of the CHMSS.
Prof. Dr. med. Kappos is the president of the MSS (CH) medical advisor board
Prof. Dr. med. Kappos is a member of medical advisor board of the German MSSOC = DMSG.
Prof. Dr. med. Kappos is a executive committee member of the biggest MS-conference in Europe.
Prof. Dr. med. Kappos is Professor of the University Basel (CH) which is government funded.
*) A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol. 2010 Mar 30;220(1-2):114-9.
That are all very responsible positions & tasks which are demanding a very high standard of expertise and trustworthiness.
Introduction for the disclosure of the CIO of physicians (Prof. Kappos, Uni Basel) with important gaps at high amounts!
http://www.facebook.com/notes/venose-multiple-sklerose-cvi-svi-ccsvi/einleitung-zur-offenlegung-von-interessenkonflikten-von-arzten-prof-kappos-uni-b/424923086183
Source: http://csvi-ms.net/forum/viewtopic.php?f=2&t=671&p=9065#p9065
++++++++++++++++++++++++++++++++++++++++++++++++++++
Learn more about Mr. Kappos, his friends from Neuroland, the rep-rats of NOVARTIS and the new poison (GILENYA/ oral fingolimod (FTY720) which kills people with MS in a more pleasant way.:
- MS Truths: Gilenya (Fingolimod) - New Oral MS Drug... "Warning"
http://savemarcelnow.blogspot.com/2011/02/gilenya-fingolimod-new-oral-ms-drug.html?spref=fb
-Gilenya - "no immediate side-effects” by CCSVI in MS Toronto
Mr. Freedman [neurologist, drug dealer] : “GILENYA brings with it many advantages. The obvious one, is that it’s easily tolerated, once a day pill, with NO IMMEDIATE side-effects.” http://www.facebook.com/notes/ccsvi-in-ms-toronto/gilenya-no-immediate-side-effects/10150151300544919
OLYMPUS DIGITAL CAMERA